National and Kapodistrian University of Athens
Υπολογισμός hrd score σε γυναικολογικούς καρκίνους
Abstract
dc:descriptionDNA damage can be categorized into two main classes based on its origin: endogenous and exogenous. In such cases the cell either leads to apoptosis, or causes cell cycle disruption or proceed to DNA damage repair through three main mechanisms (MMR,BER,NER) . The aim of this PhD thesis is the mutation detection in genes involved in the homologous recombination pathway as well as genomic instability detection. The existence of genomic instability is indicative of the inadequacy of the homologous recombination (HR) pathway. For its calculation, three biological parameters ("genomic scars") are used: the loss of heterozygosity (LOH), Telomeric Allelic Imbalance (ΤΑΙ) and the Large Scale Transitions (LST). The greatest predictive value, however, is the combined use of the above biomarkers, which is used to calculate a final value (HRD score), and seems to be increased in patients with a defective HR pathway. HRD (homologous recombination deficiency) means the inability of the cell to use the homologous recombination pathway (HR pathway) to repair DNA damage which is the leading cause of carcinogenesis. The BRCA1 and BRCA2 genes are essential for homologous recombination, and tumors which carry this type of mutations appear to be homologous recombination defect as a result of the loss of the second non mutated allele in the tumor. However, both epigenetic changes and mutations in many other additional genes involved in the HR pathway, including Fanconi anemia genes and the ΑRID1A, ATM, ATRX, BAP1, BARD1, BLM, BRIP1, CHEK1/2, MRE11A, NBN, PALB2, RAD50, RAD51, WRN genes may be responsible for the HRD phenomenon. Since 2014, four PARP inhibitors (PARPi) have been approved in the United States; olaparib, niraparib, rucaparib, and talazoparib. The purpose of this thesis is the investigation of the most appropriate algorithm for HRD score calculation as well as to determine the cut off of patients with a higher probability of PARP inhibitors treatment response. Upgraded technology equipment for next-generation sequencing (S5 System, Thermo Fisher) as well as GeneChip® System (Affymetrix) microarray platform will be used. Although most clinical trials to date have been shown to demonstrate the clinical significance of HRD in ovarian cancer, it is important to demonstrate its contribution as a biomarker to other gynaecological cancers such as breast and endometrial cancer.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Tsantikidi, Aikaterini
- Τσαντικίδη, Αικατερίνη
Subjects
dc:subject × 13Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/58491